Quantcast

Latest Hematologic disease Stories

2011-04-05 07:00:00

PALO ALTO, Calif., April 5, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today presented data at the 102nd American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida on a group of second generation analogs of ezatiostat, the most clinically advanced product in development at Telik. Ezatiostat is the first inhibitor of glutathione-S-transferase P1-1 (GST P-1), a validated enzyme target in Myelodysplastic Syndrome (MDS), to successfully complete a Phase 2 clinical...

2011-04-05 00:00:30

In response to blood cancer re-classifications by the World Health Organization, the MPD Foundation announces it is changing its name to Myeloproliferative Neoplasms (MPN) Research Foundation. Chicago, IL (PRWEB) April 4, 2011 The MPD Foundation, a patient-led foundation dedicated to the discovery of treatments and a cure for three rare blood cancers (myelofibrosis, polycythemia vera, and essential thrombocythemia) announces today a new name for the organization, which will now be known as...

2010-12-03 07:07:00

SAN DIEGO, Dec. 3, 2010 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin-associated diseases, announced the addition of three experienced executives to the management team. John P. Longenecker, Ph.D. was appointed to serve as President, CEO and Director, Richard Ghalie, MD as Chief Medical Officer, and Tamara A. Seymour as Chief Financial Officer. Dr. Longenecker most recently served...

2010-10-26 13:57:00

PALO ALTO, Calif., Oct. 26 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today that Telintra (Ezatiostat HCl), the company's lead therapeutic product candidate, has been selected by Windhover Information and its advisors as one of "The Top 10 Most Interesting Oncology Projects to Watch." Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. The company has been invited to present at...

2008-11-10 15:00:07

CHESHIRE, Conn., Nov. 10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the American Society of Hematology (ASH) has published additional data relating to Soliris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Data also have been published regarding initial experience with eculizumab in patients with two other rare diseases (Atypical Hemolytic Uremic Syndrome and Cold Agglutinin Disease). Abstracts will be presented...

2008-11-04 09:00:30

HemaQuest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle cell anemia and beta thalassemia for HQK-1001, which is an orally administered therapeutic under clinical development for these two indications. HemaQuest President and CEO Ronald Berenson, MD, said, "Orphan drug designations confirm the urgent medical need to develop new therapies to treat these two serious and life-threatening hemoglobin...

2008-08-07 06:00:10

CHESHIRE, Conn., Aug. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued Patent Number 7,408,041 titled, "Polypeptides and Antibodies Derived from Chronic Lymphocytic Leukemia Cells and Uses Thereof." The patent is assigned to Alexion and includes claims that encompass the composition-of-matter of Alexion's anti-CD200 humanized monoclonal antibody, which is known by its working name, ALXN6000. "Alexion continues...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related